<DOC>
	<DOCNO>NCT01900054</DOCNO>
	<brief_summary>The objective study evaluate long-term safety efficacy TAU-284 ( Bepotastine besilate ) pediatric patient perennial allergic rhinitis 12 week administration .</brief_summary>
	<brief_title>A Long-Term Study TAU-284 Pediatric Patients With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>This multicenter , open-label , single-arm , uncontrolled study evaluate safety efficacy TAU-284 ( 20 mg/day ) pediatric patient perennial allergic rhinitis 12 week administration .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>Patients age 7 15 year Patients receive diagnosis perennial allergic rhinitis accord diagnostic criterion Patients mean total score three major nasal symptom [ sneeze , rhinorrhea , nasal congestion ] least 3 basis symptom record nasal allergy diary observation period etc . Patients vasomotor rhinitis eosinophilic rhinitis Patients concurrent nasal disease may affect efficacy TAU284 Patients history nasal surgical procedure Patients current previous history drug allergy Patients concurrently renal function abnormality may cause safety problem etc .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>TAU-284</keyword>
	<keyword>Bepotastine besilate</keyword>
	<keyword>Histamine H1 receptor antagonist</keyword>
	<keyword>child</keyword>
</DOC>